Fate Therapeutics Initiates Phase 2 Trial for iPSC-Derived Off-the-Shelf CAR T-Cell Therapy FT819 in Lupus Nephritis, Gains FDA IND Approval for Autoimmune FT839

August 17, 2026

Fate Therapeutics, Inc. (Press Release) USA

Overview

Fate Therapeutics reported significant advancements in its iPSC-derived off-the-shelf CAR T-cell immunotherapy pipeline, with the first patient dosed in the Phase 2 RECLAIM-LN study of FT819 for lupus nephritis. Additionally, the FDA approved the Investigational New Drug (IND) application for FT839, paving the way for a Phase 1/2 trial in autoimmune diseases. These developments signify Fate Therapeutics’ strategic expansion of iPSC-derived cell therapies beyond hematologic malignancies into broader autoimmune indications.

In Depth

Key Findings

Fate Therapeutics unveiled substantial progress in its induced pluripotent stem cell (iPSC)-derived, off-the-shelf CAR T-cell immunotherapy programs during its second-quarter 2026 financial results announcement. A pivotal achievement includes the dosing of the first patient in the Phase 2 RECLAIM-LN clinical trial for FT819, targeting lupus nephritis. Furthermore, the U.S. Food and Drug Administration (FDA) granted Investigational New Drug (IND) clearance for FT839, initiating its progression into Phase 1/2 clinical studies for autoimmune diseases.

Technical / Clinical Details

FT819 is an allogeneic (off-the-shelf) CAR T-cell therapy derived from iPSCs, designed to circumvent the logistical complexities and high costs associated with autologous cell therapies. Lupus nephritis, a severe complication of systemic lupus erythematosus, currently lacks sufficiently effective treatments for many patients. FT819 aims to modulate immune responses by targeting B-cells, addressing a fundamental aspect of the disease pathology. FT839 represents another iPSC-derived cellular therapy, broadly targeting autoimmune conditions, and its IND approval validates the versatility of Fate’s iPSC platform for diverse therapeutic applications. These clinical advancements are further supported by clinical data on systemic sclerosis presented at ISSCR 2026.

Background & Context

While autologous CAR T-cell therapies have revolutionized treatment for hematologic malignancies, their personalized nature and complex manufacturing pose significant barriers to broad accessibility. Fate Therapeutics’ off-the-shelf iPSC-derived CAR T-cells offer a compelling solution by enabling scalable, readily available treatments. Autoimmune diseases, characterized by chronic inflammation and tissue damage, often present with an unmet need for curative therapies that can halt disease progression. iPSC-derived cell therapies hold the promise of fundamentally reprogramming the immune system, potentially shifting current treatment paradigms and offering a more profound, lasting impact on patients’ lives.

Strategic Significance & Outlook

The progression of FT819 into Phase 2 and the initiation of clinical trials for FT839 solidify Fate Therapeutics’ position as a leader in iPSC-derived cell therapy. Successful outcomes from these programs could establish new therapeutic modalities for autoimmune diseases, an area with high unmet medical need beyond oncology. The off-the-shelf approach is critical for expanding patient access and reducing manufacturing expenses, potentially allowing for broader market penetration. Future clinical data disclosures and ongoing regulatory engagements will be crucial in defining the pathway for these innovative therapies to reach patients globally.

Source: https://ir.fatetherapeutics.com/news-releases/news-release-details/fate-therapeutics-reports-second-quarter-2026-financial-results

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.